Progyny (PGNY) Set to Announce Earnings on Thursday

Progyny (NASDAQ:PGNY) is scheduled to be releasing its earnings data after the market closes on Thursday, May 9th. Analysts expect Progyny to post earnings of $0.14 per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.04. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The firm had revenue of $269.94 million for the quarter, compared to analyst estimates of $274.08 million. During the same period last year, the firm posted $0.03 EPS. Progyny’s quarterly revenue was up 26.0% on a year-over-year basis. On average, analysts expect Progyny to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Progyny Stock Performance

Progyny stock opened at $33.06 on Wednesday. Progyny has a one year low of $29.44 and a one year high of $44.95. The business has a fifty day moving average of $34.95 and a two-hundred day moving average of $35.62. The company has a market cap of $3.18 billion, a P/E ratio of 53.32, a price-to-earnings-growth ratio of 1.31 and a beta of 1.51.

Insider Activity at Progyny

In related news, President Michael E. Sturmer sold 4,515 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $31.95, for a total value of $144,254.25. Following the completion of the transaction, the president now owns 380,038 shares of the company’s stock, valued at approximately $12,142,214.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Mark S. Livingston sold 11,165 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $37.62, for a total value of $420,027.30. Following the completion of the transaction, the chief financial officer now owns 50,119 shares of the company’s stock, valued at approximately $1,885,476.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Michael E. Sturmer sold 4,515 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $31.95, for a total transaction of $144,254.25. Following the completion of the transaction, the president now directly owns 380,038 shares of the company’s stock, valued at approximately $12,142,214.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 102,770 shares of company stock valued at $3,853,985. 12.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

PGNY has been the subject of a number of recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $48.00 target price on shares of Progyny in a report on Wednesday, February 28th. SVB Leerink initiated coverage on Progyny in a report on Monday, February 26th. They issued an “outperform” rating and a $49.00 target price for the company. Truist Financial reissued a “buy” rating and issued a $46.00 target price on shares of Progyny in a report on Wednesday, April 17th. Leerink Partnrs reaffirmed an “outperform” rating on shares of Progyny in a research note on Monday, February 26th. Finally, KeyCorp cut their price target on Progyny from $45.00 to $43.00 and set an “overweight” rating for the company in a research note on Wednesday, February 28th. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $48.30.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.